Apriem Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Apriem Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-200	Closed	-$33K	–	569
2014 Q4	$33K	Sell	200 -18,380	-99%	-$3.05M	0.01%	238
2014 Q3	$2.98M	Sell	18,580 -190	-1%	-$29.2K	1.14%	32
2014 Q2	$2.76M	Buy	18,770 +5,795	+45%	+$804K	1.05%	35
2014 Q1	$1.8M	Buy	+12,975	New	+$1.95M	0.68%	48

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

WBC

Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Apriem Advisors's JAZZ Position: Q1 2015 in Review

Apriem Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2015, closing a stake of 200 shares — an estimated $33K sold.

Apriem Advisors first reported a position in JAZZ in Q1 2014 and held it in 4 quarters. The position peaked at $2.98M in Q3 2014. 354 funds tracked by Wall St. Rank hold JAZZ as of Q1 2015.

Apriem Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Apriem Advisors sold 200 Jazz Pharmaceuticals shares in Q1 2015, an estimated $33K.
Apriem Advisors first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 4 quarters.
Apriem Advisors's Jazz Pharmaceuticals position peaked at $2.98M in Q3 2014.
354 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2015.

Based on Apriem Advisors's 13F filing for Q1 2015, filed 7 May 2015.